Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Ruggiero

Showing results (11-20 of 134) with videos related to

Pageof 14
Sort By:
Clinical and Experimental Dermatology|July 7, 2022
Patient satisfaction with remote dermatology consultations during the COVID-19 pandemic. Comment on 'A qualitative assessment of patient satisfaction with remote dermatology consultations used during the UK's first wave of the COVID-19 pandemic in a single, secondary-care dermatology department'Fabrizio Martora, Angelo Ruggiero, Gabriella Fabbrocini, et al.
Case Reports in Dermatology|October 1, 2020
A Case of Ofuji Disease Successfully Treated with the Combination of Low-Dose Indomethacin and Topical TacrolimusClaudio Marasca, Angelo Ruggiero, Gabriella Fabbrocini, et al.
Dermatologic Therapy|December 14, 2020
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective studyAngelo Ruggiero, Gabriella Fabbrocini, Eleonora Cinelli, et al.
Dermatologic Therapy|November 20, 2021
Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective studyAngelo Ruggiero, Gabriella Fabbrocini, Eleonora Cinelli, et al.
Archives of Dermatological Research|December 12, 2024
Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective studyLuca Potestio, Angelo Ruggiero, Fabrizio Martora, et al.
Expert Opinion on Drug Safety|October 17, 2022
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledgeAngelo Ruggiero, Matteo Megna, Gabriella Fabbrocini, et al.
Dermatologic Therapy|January 31, 2020
A case of erythrodermic psoriasis successfully treated with guselkumabMatteo Megna, Angelo Ruggiero, Elisa Camela, et al.
Clinical and Experimental Dermatology|June 14, 2022
Tacrolimus ointment may improve the effectiveness of adalimumab in patients with hidradenitis suppurativa: a novel promising treatmentAngelo Ruggiero, Claudio Marasca, Alessia Villani, et al.
Dermatologic Therapy|April 19, 2022
Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life studyMatteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Photodiagnosis and Photodynamic Therapy|July 19, 2022
Photodynamic therapy with 16 methyl aminolaevulinic acid and topic calcipotriol: A novel promising synergistic approach for the management of Hailey-Hailey diseaseFabrizio Martora, Angelo Ruggiero, Luigi Fornaro, et al.
Pageof 14

Showing results (11-20 of 134) with videos related to

Sort By:
Pageof 14
Clinical and Experimental Dermatology|July 7, 2022
Patient satisfaction with remote dermatology consultations during the COVID-19 pandemic. Comment on 'A qualitative assessment of patient satisfaction with remote dermatology consultations used during the UK's first wave of the COVID-19 pandemic in a single, secondary-care dermatology department'Fabrizio Martora, Angelo Ruggiero, Gabriella Fabbrocini, et al.
Case Reports in Dermatology|October 1, 2020
A Case of Ofuji Disease Successfully Treated with the Combination of Low-Dose Indomethacin and Topical TacrolimusClaudio Marasca, Angelo Ruggiero, Gabriella Fabbrocini, et al.
Dermatologic Therapy|December 14, 2020
Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective studyAngelo Ruggiero, Gabriella Fabbrocini, Eleonora Cinelli, et al.
Dermatologic Therapy|November 20, 2021
Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective studyAngelo Ruggiero, Gabriella Fabbrocini, Eleonora Cinelli, et al.
Archives of Dermatological Research|December 12, 2024
Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective studyLuca Potestio, Angelo Ruggiero, Fabrizio Martora, et al.
Expert Opinion on Drug Safety|October 17, 2022
Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledgeAngelo Ruggiero, Matteo Megna, Gabriella Fabbrocini, et al.
Dermatologic Therapy|January 31, 2020
A case of erythrodermic psoriasis successfully treated with guselkumabMatteo Megna, Angelo Ruggiero, Elisa Camela, et al.
Clinical and Experimental Dermatology|June 14, 2022
Tacrolimus ointment may improve the effectiveness of adalimumab in patients with hidradenitis suppurativa: a novel promising treatmentAngelo Ruggiero, Claudio Marasca, Alessia Villani, et al.
Dermatologic Therapy|April 19, 2022
Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life studyMatteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Photodiagnosis and Photodynamic Therapy|July 19, 2022
Photodynamic therapy with 16 methyl aminolaevulinic acid and topic calcipotriol: A novel promising synergistic approach for the management of Hailey-Hailey diseaseFabrizio Martora, Angelo Ruggiero, Luigi Fornaro, et al.
Pageof 14